Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides

Clinical Cancer Research

Volumn 15, Issue 16, 2009, Pages 5240-5249

  Mansi, Rosalba ^a   Wang, Xuejuan ^a   Forrer, Flavio ^a   Kneifel, Stefan ^a   Tamma, Maria Luisa ^a   Waser, Beatrice ^b   Cescato, Renzo ^b   Reubi, Jean Claude ^b   Maecke, Helmut R ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BOMBESIN; CALCIUM; GALLIUM 68; GASTRIN; GASTRIN RELEASING PEPIDE RECEPTOR; INDIUM 111; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; DRUG TARGETING; EVALUATION RESEARCH; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BOMBESIN; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; FEMALE; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASMS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RECEPTORS, BOMBESIN; RECEPTORS, G-PROTEIN-COUPLED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSPLANTATION, HETEROLOGOUS;

EID: 69349102846     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3145     Document Type: Article

References (48)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427. (Pubitemid 37056239)
2. Weiner RE, Thakur ML. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs 2005;19:145-163 (Pubitemid 40994231)
3. Reubi JC, Maecke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46:67-75S.
4. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971-994 (Pubitemid 30671305)
5. Boerman OC, Oyen WJ, Corstens FH. Radiolabeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin Nucl Med 2000;30:195-208.
6. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006;103:16436-16441
7. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in thehuman prostate: relation to neoplastic transformation. Cancer Res 1999;59:1152-1159 (Pubitemid 29135980)
8. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrinreleasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 2000;42:295-303. (Pubitemid 30104573)
9. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 1999;155:2067-2076
10. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 1995; 55:280-287
11. Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 2004;31: 803-810 (Pubitemid 38758349)
12. Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985;316:823-826 (Pubitemid 15003742)
13. Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 2007;18:1457-1466 (Pubitemid 47365477)
14. Stangelberger A, Schally AV, Varga JL, et al. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3human prostate cancer in nude mice. Clin Cancer Res 2005;11:49-57. (Pubitemid 40075777)
15. Bajo AM, Schally AV, Groot K, Szepeshazi K. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br J Cancer 2004;90:245-252 (Pubitemid 38174968)
16. Schwartsmann G, DiLeone LP, Horowitz M, et al. A phase I trial of the bombesin/gastrinreleasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006;24:403-412 (Pubitemid 43876076)
17. 99mTc: a preclinical study. J Med Chem 2005;48:100-110
18. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006;47:1144-1152
19. 3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004;45:1390-1397
20. Zhang X, Cai W, Cao F, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressingprostate cancer. J Nucl Med 2006;47:492-501. (Pubitemid 46768492)
21. Lin KS, Luu A, Baidoo KE, et al. A new high affinity technetium-99m- bombesin analogue with low abdominal accumulation. Bioconjug Chem 2005;16:43-50. (Pubitemid 40129676)
22. 68Ga-labeled bombesin( 6-14) analog. J Nucl Med 2005;46:691-699
23. Parry JJ, Andrews R, Rogers BE MicroPET Imaging of Breast Cancer Using Radiolabeled Bombesin Analogs Targeting the Gastrin-releasing Peptide Receptor. Breast Cancer Res Treat 2006; 2007;101:175-183. (Pubitemid 46115423)
24. Zhang H, Chen J, Waldherr C, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004;64:6707-6715 (Pubitemid 39302601)
25. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000;27:1694-1699 (Pubitemid 30812526)
26. Van de Wiele C, Phonteyne P, Pauwels P, et al. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med 2008;49:260-264 (Pubitemid 351225665)
27. 18F-FDG. J Nucl Med 2007;48:1245-1250
28. Bodei L, Ferrari M, Nunn AD, et al. 177Lu- AMBA Bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging 2007;34:S221.
29. Baum RP, Prasad V, Mutloka N, Frischknecht M, Maecke HR, Reubi JC. Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET/CT. J Nucl Med 2007;48:79P.
30. Azay J, Nagain C, Llinares M, et al. Comparative study of in vitro and in vivo activities of bombesin pseudopeptide analogs modified on the C-terminal dipeptide fragment. Peptides 1998;19:57-63.
31. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008;49:318-326 (Pubitemid 351225672)
32. Llinares M, Devin C, Chaloin O, et al. Syntheses and biological activities of potent bombesin receptor antagonists. J Pept Res 1999;53:275-283 (Pubitemid 29189917)
33. Atherton E, Sheppard R. Fluorenylmethoxycarbonyl- polyamide solid phase peptide synthesis. General principles and development. Oxford: Oxford Information Press; 1989.
34. Heppeler A, Froidevaux S, Mäcke H, et al. Radiometal- labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumourtargeting properties and potential for receptormediated internal radiotherapy. Chemistry 1999; 5:1974-1981 (Pubitemid 129502685)
35. 68Ga for medical application. J Nucl Med 2007;48:1741-1748
36. 14] Bombesin(6-14). Clin Cancer Res 2002; 8:1139-1146
37. Vigna SR, Mantyh CR, Giraud AS, Soll AH, Walsh JH, Mantyh PW. Localization of specific binding sites for bombesin in the canine gastrointestinal tract. Gastroenterology 1987;93: 1287-1295 (Pubitemid 17167270)
38. Michel N, Ganter K, Venzke S, Bitzegeio J, Fackler OT, Keppler OT. The Nef protein of human immunodeficiency virus is a broad-spectrum modulator of chemokine receptor cell surface levels that acts independently of classical motifs for receptor endocytosis and Gαi signaling. Mol Biol Cell 2006;17:3578-3590 (Pubitemid 44156450)
39. 177Lu- AMBA in PC-3tumor bearing mice. J Nucl Med 2007;48:79P.
40. Abd-Elgaliel WR, Gallazzi F, Garrison JC, et al. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug Chem 2008;19:2040-2048
41. Basso N, Lezoche E, Speranza V. Studies with bombesin in man. World J Surg 1979;3:579-585
42. Maina T, Nock BA, Zhang H, et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 2005;46:823-830 (Pubitemid 43750761)
43. Yang Y-S, Zhang X, Xiong Z, Chen X. Comparative in vitro and in vivo evaluation of two 64Culabeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 2006;33:371-380
44. 64Cu-labeled bombesin analogue. Bioconjug Chem 2003;14: 756-763
45. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 2007;104:12462-12467
46. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 2005;4:919-927 (Pubitemid 41637694)
47. Ginj M, Zhang H, Eisenwiener KP, et al. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin Cancer Res 2008;14:2019-2027 (Pubitemid 351551111)
48. Roettger BF, Ghanekar D, Rao R, et al. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 1997;51:357-362 (Pubitemid 27118469)